Unknown

Dataset Information

0

The protective effect of rheumatic disease agents in COVID-19.


ABSTRACT: Several immunosuppressive therapies have been investigated as potential treatments for patients with severe and critical coronavirus disease 2019 (COVID-19). Notable examples include corticosteroids, interleukin 6 (IL-6), interleukin 1 (IL-1), Janus kinase (JAK), and tumor necrosis factor alpha (TNF-α) inhibitors. The aim of this narrative review is to analyze the mechanistic rationale and available evidence for these selected anti-rheumatic drugs for the treatment of COVID-19. Currently, only corticosteroids have consistently proven to be effective in decreasing mortality and are recommended in clinical guidelines for the treatment of severe and critical COVID-19. Multiple randomized controlled trials (RCTs) are ongoing to determine the role of other immunosuppressants.

SUBMITTER: Valenzuela-Almada MO 

PROVIDER: S-EPMC7833968 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC7245236 | biostudies-literature
| S-EPMC7799147 | biostudies-literature
| S-EPMC8023691 | biostudies-literature
| S-EPMC8065312 | biostudies-literature
| S-EPMC9116968 | biostudies-literature
| S-EPMC8992351 | biostudies-literature
| S-EPMC10189063 | biostudies-literature
| S-EPMC7476772 | biostudies-literature
| S-EPMC7500497 | biostudies-literature